Information  X 
Enter a valid email address

Diurnal Group PLC (DNL)

  Print      Mail a friend

Friday 26 June, 2020

Diurnal Group PLC

Director Dealings

RNS Number : 2656R
Diurnal Group PLC
26 June 2020
 

26 June 2020

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Director Dealings

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the following Directors' dealings undertaken for tax planning purposes:

 

John Goddard, Non-executive Director, sold 38,461 Ordinary Shares at a price of 33 pence per Ordinary Share and purchased 38,361 Ordinary Shares at a price of 33.08 pence per Ordinary Share. Following the transactions, his total beneficial interest is 188,489 Ordinary Shares, representing 0.2% of the total voting rights as at 26 June 2020.

 

 

Details of the full notifications received by the Company are set out below:

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 John Goddard

2

 

Reason for the notification

 

a)

 

Position/status

 

Non-executive Director

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 5 pence each in Diurnal Group plc



Identification code

GB00BDB6Q760



b)

 

Nature of the transaction

 

Sale and purchase of ordinary shares

 

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




Sale 33p

Purchase 33.08p

38,461

38,361

 

 






d)

 

Aggregated information




- Aggregated volume

As above



- Price




e)

 

Date of the transaction

 

26 June 2020

f)

 

Place of the transaction

 

XLON

 

 

For further information, please visit www.diurnal.co.uk or contact:



Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer


Richard Bungay, Chief Financial Officer




Panmure Gordon (UK) Limited (Nominated Adviser and Sole Broker)

+44 (0) 20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl


Corporate Broking: James Stearns




FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway


Victoria Foster Mitchell


 

 

Notes to Editors

 

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-headquartered, European-based specialty pharma company developing pharmaceutical products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHFLFFVRDIRFII

a d v e r t i s e m e n t